English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe latest installment of $225,000 brings the total to almost $2 million over the past nine years. It will fund research into the immune microenvironment of triple-negative breast cancer in order to identify new strategies to enhance cancer-fighting immune responses for this aggressive breast cancer, which traditionally has few options for treatment.
“We are delighted and grateful to receive this grant from the Foundation, which recognizes the expertise and the commitment of both the Icahn School of Medicine at Mount Sinai and the Dubin Breast Center with regard to developing novel therapeutics for a diverse group of patients with high-risk breast cancers,” said Dr. Port, Chief of Breast Surgery for the Mount Sinai Health System and Director of the Dubin Breast Center of The Tisch Cancer Institute at Icahn Mount Sinai.
“This funding also recognizes our innovative efforts to advance the field’s understanding of this disease, such as our Breast Cancer Biorepository, an impressive bank of patient breast tumor tissue and blood samples that is enabling us to make research breakthroughs,” Dr. Port said. “This grant, combined with our extensive resources and knowledge, provides us with invaluable support to identify treatments that could have significant benefits for our patients, and for millions of women worldwide.”
Typically diagnosed among women under the age of 50, triple-negative breast cancer is a subtype of breast cancer that has an estimated prevalence between 10-15 percent of all breast cancer cases. It can be particularly challenging to treat, in part because it is aggressive and thus has a higher risk of relapse, but also because the options available for treatment are limited. Although immunotherapy is increasingly used in the treatment of triple-negative breast cancer, not all patients respond to or benefit from this approach. Thus, more research is required among patients to understand how their immune system interacts with breast cancer cells and how it works to control cancer growth and spread both within the tumor itself and in other parts of the body.
“Our BCRF-funded studies will explore those interactions between breast cancer cells and the immune system, specifically focusing on cancer stem cells,” said Dr. Irie, Associate Professor of Medicine (Hematology and Medical Oncology), and Oncological Sciences, at the Dubin Breast Center. “Breast cancer stem cells are less likely to be eliminated by chemotherapy or immunotherapy, and our goal is to develop strategies that simultaneously kill triple-negative breast cancer stem cells and enhance anti-tumor immune responses. We have identified several promising candidate drugs that induce these effects in preclinical models of triple-negative breast cancer, and we are working to clinically translate them so that we can achieve improved results for our patients.”
Founded in 1993 by Evelyn H. Lauder, BCRF is the largest private funder of breast cancer research in the world. By investing in the best minds in science—those investigating prevention, diagnosis, treatment, survivorship, and metastasis—and fostering cross-disciplinary collaboration, BCRF is accelerating the field to find the answers that are urgently needed to achieve the end of breast cancer.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
